Feasibility and safety of delivering full-dose anticoagulation therapy in children treated according to Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium therapy protocols-Reference-Cited by-同舟云学术

Feasibility and safety of delivering full-dose anticoagulation therapy in children treated according to Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium therapy protocols

Published:2018-10-25 Issue:2 Volume:66 Page:e27483
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Bhatt Mihir D.¹^ORCID,Parmar Neha¹,Fowler Jo-Ann¹,Chan Anthony K. C.¹,Athale Uma H.¹^ORCID

Affiliation:

1. Division of Pediatric Hematology/Oncology; McMaster Children's Hospital and McMaster University; Hamilton Ontario Canada

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.27483/fullpdf

Reference16 articles.

1. Thrombosis in children with acute lymphoblastic leukemia. Part I: epidemiology of thrombosis in children with acute lymphoblastic leukemia;Athale;Thromb Res,2003

2. Thrombosis in children with malignancy;Bajzar;Curr Opin Pediatr,2006

3. A practical approach to diagnosis and treatment of symptomatic thromboembolic events in children with acute lymphoblastic leukemia: recommendations of the ‘coagulation defects’ AEIOP Working Group;Giordano;Recent Patents Cardiovasc Drug Discov,2007

4. Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: critical review of the literature;Annibali;Crit Rev Oncol Hematol,2018

5. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial;Place;Lancet Oncol,2015